Skip to main content Back to Top
Advertisement

5/17/2016

Deferoxamine mesylate injection

Products Affected - Description

    • Desferal injection, Novartis, 2 gram, vial, 4 count, NDC 00078-0347-51

Reason for the Shortage

    • Fresenius Kabi has deferoxamine available.
    • Hospira has deferoxamine available.
    • Novartis discontinued Desferal 2 gram vials in 2015. The 500 mg vials are available.
    • Teva discontinued all deferoxamine presentations in 2013.
    • West-Ward discontinued deferoxamine in September 2014.
    • Watson discontinued all deferoxamine presentations.

Available Products

    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated May 17, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 23, 2010 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins